Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Go back to Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital| (NASDAQ: ALZN) | Delayed: 1.13 -0.07 (5.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.20 | 52 Week High | $ | |||
| Open | $1.32 | 52 Week Low | $ | |||
| Day High | $1.32 | P/E | N/A | |||
| Day Low | $1.10 | EPS | $ | |||
| Volume | 1,752,466 | |||||
